Skip to main content
. 2020 Nov 28;64:30–35. doi: 10.1016/j.jelectrocard.2020.11.012

Fig. 4.

Fig. 4

Death from any cause in double and triple therapy groups (A), and in patients with or without high risk QTc prolongation (B).